Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucagon-Like Peptide-1 Agonists and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Type 2 diabetes remission one year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice

    Research output: Contribution to journalReviewResearchpeer-review

  3. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Energy expenditure and loss of muscle and fat mass in patients with walled-off pancreatic necrosis: A prospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose doctors to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9,347 GLP-1RA-treated and 9,353 placebo-treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increase the risk of AP in patients with type 2 diabetes.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume19
Issue number6
Pages (from-to)906-908
ISSN1462-8902
DOIs
Publication statusPublished - 1 Jun 2017

ID: 49695776